

DAFTAR PUSTAKA

- Aaberg, K.M., Gunnes, N., Bakken, I.J., Sooras, C.L., Bernsten, A., Magnus P., *et al.*, 2017. Incidence and prevalence of childhood epilepsy: A nationwide cohort study. *Pediatrics*, 139(5), pp.1-9.
- Abdelsalam, M., Abd Elmagid, D.S., Magdy, H., El-Sabbagh, A.M. and Mostafa, M., 2020. The association between toll-like receptor 4 (TLR4) genotyping and the risk of epilepsy in children. *Egyptian Journal of Medical Human Genetics*, 21(1), pp.4–11.
- Abokrysha, N.T., Taha, N., Shamloul, R., Elsayed, S., Osama, W. and Hatem, G., 2023. Clinical, radiological and electrophysiological predictors for drug-resistant epilepsy. *Egyptian Journal of Neurology, Psychiatry and Neurosurgery*, 59(1), pp.1–7. Terdapat di: <https://doi.org/10.1186/s41983-023-00647-1>.
- Adelöw, C., Åndell, E., Åmark, P., Andersson, T., Hellebro, E., Ahlbom, A. *et al.*, 2009. Newly diagnosed single unprovoked seizures and epilepsy in Stockholm, Sweden: First report from the Stockholm Incidence Registry of Epilepsy (SIRE). *Epilepsia*, 50(5), pp.1094–1101.
- Adewuya, A.O., Oseni, S.B.A. and Okeniyi, J.A.O., 2006. School performance of Nigerian adolescents with epilepsy. *Epilepsia*, 47(2), pp.415–420.
- Aguiar, B.V.K., Guerreiro, M.M., McBrian, D. and Montenegro, M.A., 2007. Seizure impact on the school attendance in children with epilepsy. *Seizure*, 16(8), pp.698–702.
- Aldenkamp, A.P., Weber, B., Overweg-Plandsoen, W.C.G., Reijs, R. and van Mil, S., 2005. Educational underachievement in children with epilepsy: A model to predict the effects of epilepsy on educational achievement. *Journal of Child Neurology*, 20(3), pp.175–180.
- Amtul, Z., 2018. *Nature's Medicines to Treat Epileptic Seizures* 1st ed., Elsevier B.V. Terdapat di: <http://dx.doi.org/10.1016/B978-0-444-64058-1.00004-2>.
- Ana, R., Mendes, M., Sousa, J., Pais, A., Falcão, A., Fortuna, A., *et al.*, 2019. Rethinking carbamazepine oral delivery using polymer-lipid hybrid nanoparticles. *International Journal of Pharmaceutics*, 554(November 2018), pp.352–365. Terdapat di: <https://doi.org/10.1016/j.ijpharm.2018.11.028>.
- Andersson, U. and Tracey, K.J., 2011. HMGB1 is a therapeutic target for sterile inflammation and infection. *Annual Review of Immunology*, 29, pp.139–162.
- Angus-Leppan, H. and Parsons, L.M., 2008. Epilepsy: epidemiology, classification and natural history. *Medicine*, 36(11), pp.571–578. Terdapat di: <http://dx.doi.org/10.1016/j.mpmed.2008.08.003>.
- Balosso, S., Liu, J., Bianchi, M.E. and Vezzani, A., 2014. Disulfide-containing high mobility group box-1 promotes N-methyl-d-aspartate receptor function and excitotoxicity by activating toll-like receptor 4-dependent signaling in hippocampal neurons. *Antioxidants and Redox Signaling*, 21(12), pp.1726–1740.
- Bayat, A., Bayat, M., Rubboli, G. and Møller, R.S., 2021. Epilepsy syndromes in the first year of life and usefulness of genetic testing for precision therapy. *Genes*,

12(7).

- Benbadis, S.R. and Tatum, W.O., 2003. Overintepretation of EEGS and misdiagnosis of epilepsy. *Journal of Clinical Neurophysiology*, 20(1), pp.42–44.
- Berg, A.T., Berkovic, S.F., Brodie, M.J., Buchhalter, J., Cross, H., Boas, W.V.E., *et al.*, 2010. Revised terminology and concepts for organization of seizures and epilepsies: Report of the ILAE Commission on Classification and Terminology, 2005-2009. *Epilepsia*, 51(4), pp.676–685.
- Berg, A.T., Shinnar, S., Levy, S.R., Testa, F.M., Smith-Rapaport, S., Beckerman, B., *et al.*, 2001. Defining early seizure outcomes in pediatric epilepsy: The good, the bad and the in-between. *Epilepsy Research*, 43(1), pp.75–84.
- Blum, A.S. and Rutkove, S.B., 2007. *The clinical neurophysiology primer*. Humana Press Inc., Totowa, NJ, pp 43-53
- Brann, D.W., Dhandapani, K., Wakade, C., Mahesh, V.B. and Khan, M.M., 2007. Neurotrophic and neuroprotective actions of estrogen: Basic mechanisms and clinical implications. *Steroids*, 72(5), pp.381–405.
- Casey, B.J., Giedd, J.N. and Thomas, K.M., 2000. Structural and functional brain development and its relation to cognitive development. *Biological Psychology*, 54(1–3), pp.241–257.
- Chen, Z., Brodie, M.J., Liew, D. and Kwan, P., 2018. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs a 30-year longitudinal cohort study. *JAMA Neurology*, 75(3), pp.279–286.
- Chiavegato, A., Zurolo, E., Losi, G., Aronica, E. and Carmignoto, G., 2014. The inflammatory molecules IL-1 β and HMGB1 can rapidly enhance focal seizure generation in a brain slice model of temporal lobe epilepsy. *Frontiers in Cellular Neuroscience*, 8(JUN), pp.1–9.
- Child, N.D. and Benarroch, E.E., 2014. Differential distribution of voltage-gated ion channels in cortical neurons: Implications for epilepsy. *Neurology*, 82(11), pp.989–999.
- Ciucci, A., Gabriele, I., Percario, Z.A., Affabris, E., Colizzi, V. and Mancino, G., 2011. HMGB1 and cord blood: Its role as immuno-adjuvant factor in innate immunity. *PLoS ONE*, 6(8), pp.1–10.
- Costello, D.A., Watson, M.B., Cowley, T.R., Murphy, N., Royal, C.M., Garlanda, C., *et al.*, 2011. Interleukin-1 α and HMGB1 mediate hippocampal dysfunction in SIGIRR-deficient mice. *Journal of Neuroscience*, 31(10), pp.3871–3879.
- Dai, S., Zheng, Y., Wang, Y. and Chen, Z., 2021. HMGB1, neuronal excitability and epilepsy. *Acta Epileptologica*, 3(1).
- Deoni, S.C.L., Dean, D.C., Remer, J., Dirks, H. and O’Muircheartaigh, J., 2015. Cortical maturation and myelination in healthy toddlers and young children. *NeuroImage*, 115, pp.147–161. Terdapat di: <http://dx.doi.org/10.1016/j.neuroimage.2015.04.058>.
- Dey, A., Kang, X., Qiu, J., Du, Y. and Jiang, J., 2016. Anti-Inflammatory Small Molecules to Treat Seizures and Epilepsy: From Bench to Bedside. *Trends in Pharmacological Sciences*, 37(6), pp.463–484.

- Di Maio, R., 2014. Neuronal mechanisms of epileptogenesis. *Frontiers in Cellular Neuroscience*, 8(FEB), pp.1–2.
- Douet, V., Chang, L., Cloak, C. and Ernst, T., 2014. Genetic influences on brain developmental trajectories on neuroimaging studies: From infancy to young adulthood. *Brain Imaging and Behavior*, 8(2), pp.234–250.
- Dumitriu, I.E., Baruah, P., Bianchi, M.E., Manfredi, A.A. and Rovere-Querini, P., 2005. Requirement of HMGB1 and RAGE for the maturation of human plasmacytoid dendritic cells. *European Journal of Immunology*, 35(7), pp.2184–2190.
- Fattorusso, A., Matricardi, S., Mencaroni, E., Dell’Isola, G.B., Di Cara, G., Striano, P., *et al.*, 2021. The Pharmacoresistant Epilepsy: An Overview on Existant and New Emerging Therapies. *Frontiers in Neurology*, 12(June), pp.1–15.
- Festoff, B.W., Sajja, R.K., van Dreden, P. and Cucullo, L., 2016. HMGB1 and thrombin mediate the blood-brain barrier dysfunction acting as biomarkers of neuroinflammation and progression to neurodegeneration in Alzheimer’s disease. *Journal of Neuroinflammation*, 13(1), pp.1–12. Terdapat di: <http://dx.doi.org/10.1186/s12974-016-0670-z>.
- Fisher, R.S., Acevedo, C., Arzimanoglou, A., Bogacz, A., Cross, J.H., Elger, C.E, *et al.*, 2014. ILAE Official Report: A practical clinical definition of epilepsy. *Epilepsia*, 55(4), pp.475–482.
- Fisher, R.S., Cross, J.H., French, J.A., Higurashi, N., Hirsch, E., Jansen, F.E., *et al.*, 2017. Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. *Epilepsia*, 58(4), pp.522–530.
- Fisher, R.S., Van Emde Boas, W., Blume, W., Elger, C., Genton, P., Lee, P., *et al.*, 2005. Response: Definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE) [4]. *Epilepsia*, 46(10), pp.1701–1702.
- Frank, M.G., Weber, M.D., Watkins, L.R. and Maier, S.F., 2015. Stress sounds the alarm: The role of the danger-associated molecular pattern HMGB1 in stress-induced neuroinflammatory priming. *Brain, Behavior, and Immunity*, 48(March), pp.1–7. Terdapat di: <http://dx.doi.org/10.1016/j.bbi.2015.03.010>.
- Freestone, D.R., Karoly, P.J. and Cook, M.J., 2017. A forward-looking review of seizure prediction. *Current Opinion in Neurology*, 30(2), pp.167–173.
- Freitag, C.M., May, T.W., Pfäfflin, M., König, S. and Rating, D., 2001. Incidence of epilepsies and epileptic syndromes in children and adolescents: A population-based prospective study in Germany. *Epilepsia*, 42(8), pp.979–985.
- Fu, L., Liu, K., Wake, H., Teshigawara, K., Yoshino, T., Takahashi, H., *et al.*, 2017. Therapeutic effects of anti-HMGB1 monoclonal antibody on pilocarpine-induced status epilepticus in mice. *Scientific Reports*, 7(1), pp.1–13.
- Fu, L. and Nishibori, M., 2019. The role of high mobility group box-1 in epileptogenesis. *Acta Medica Okayama*, 73(5), pp.383–386.
- Gaillard, W.D., Chiron, C., Helen Cross, J., Simon Harvey, A., Kuzniecky, R., Hertz-

- Pannier, L. and Gilbert Vezina, L., 2009. Guidelines for imaging infants and children with recent-onset epilepsy. *Epilepsia*, 50(9), pp.2147–2153.
- Galic, M.A., Riazi, K. and Pittman, Q.J., 2012. Cytokines and brain excitability. *Frontiers in Neuroendocrinology*, 33(1), pp.116–125. Terdapat di: <http://dx.doi.org/10.1016/j.yfrne.2011.12.002>.
- Girard, J.P., 2007. A Direct Inhibitor of HMGB1 Cytokine. *Chemistry and Biology*, 14(4), pp.345–347.
- Goodman, A.M. and Szaflarski, J.P., 2021. Recent Advances in Neuroimaging of Epilepsy. *Neurotherapeutics*, 18(2), pp.811–826. Terdapat di: <https://doi.org/10.1007/s13311-021-01049-y>.
- Guerrini, R., Conti, V., Mantegazza, M., Balestrini, S., Galanopoulou, A.S. and Benfenati, F., 2023. Developmental and Epileptic Encephalopathies: From Genetic Heterogeneity To Phenotypic Continuum. *Physiological Reviews*, 103(1), pp.433–513.
- Han, Y., Yang, L., Liu, X., Feng, Y., Pang, Z. and Lin, Y., 2020. Hmgb1/cxcl12-mediated immunity and TH17 cells might underlie highly suspected autoimmune epilepsy in elderly individuals. *Neuropsychiatric Disease and Treatment*, 16, pp.1285–1293.
- Harris, H.E., Andersson, U. and Pisetsky, D.S., 2012. HMGB1: A multifunctional alarmin driving autoimmune and inflammatory disease. *Nature Reviews Rheumatology*, 8(4), pp.195–202. Terdapat di: <http://dx.doi.org/10.1038/nrrheum.2011.222>.
- Hei, Y., Chen, R., Yi, X., Long, Q., Gao, D. and Liu, W., 2018. HMGB1 Neutralization Attenuates Hippocampal Neuronal Death and Cognitive Impairment in Rats with Chronic Cerebral Hypoperfusion via Suppressing Inflammatory Responses and Oxidative Stress. *Neuroscience*, 383(May), pp.150–159. Terdapat di: <https://doi.org/10.1016/j.neuroscience.2018.05.010>.
- Hess, C.P. and Barkovich, A.J., 2010. Seizures: Emergency neuroimaging. *Neuroimaging Clinics of North America*, 20(4), pp.619–637. Terdapat di: <http://dx.doi.org/10.1016/j.nic.2010.07.013>.
- Hirose, S., 2014. *Mutant GABAA receptor subunits in genetic (idiopathic) epilepsy* 1st ed., Elsevier B.V. Terdapat di: <http://dx.doi.org/10.1016/B978-0-444-63326-2.00003-X>.
- Huang, Z., Zhong, Z., Zhang, L., Wang, X., Xu, R., Zhu, L., *et al.*, 2015. Down-regulation of HMGB1 expression by shRNA constructs inhibits the bioactivity of urothelial carcinoma cell lines via the NF- κ B pathway. *Scientific Reports*, 5(August), pp.1–10.
- Huttunen, H.J., Fages, C., Kuja-Panula, J., Ridley, A.J. and Rauvala, H., 2002. Receptor for advanced glycation end products-binding COOH-terminal motif of amphotericin inhibits invasive migration and metastasis. *Cancer Research*, 62(16), pp.4805–4811.
- Ieong, C., Sun, H., Wang, Q. and Ma, J., 2018. Glycyrrhizin suppresses the expressions of HMGB1 and ameliorates inflammatory effect after acute

- subarachnoid hemorrhage in rat model. *Journal of Clinical Neuroscience*, 47, pp.278–284. Terdapat di: <https://doi.org/10.1016/j.jocn.2017.10.034>.
- Iori, V., Maroso, M., Rizzi, M., Iyer, A.M., Vertemara, R., Carli, M., *et al.*, 2013. Receptor for Advanced Glycation Endproducts is upregulated in temporal lobe epilepsy and contributes to experimental seizures. *Neurobiology of Disease*, 58, pp.102–114. Terdapat di: <http://dx.doi.org/10.1016/j.nbd.2013.03.006>.
- Jackson, G.D., Kuzniecky, R.I. and Berkovic, S.F., 2004. Introduction to Epilepsy. *Magnetic Resonance in Epilepsy: Neuroimaging Techniques: Second Edition*, pp.1–16.
- Jo, J.H., Park, E.J., Lee, J.K., Jung, M.W. and Lee, C.J., 2001. Lipopolysaccharide inhibits induction of long-term potentiation and depression in the rat hippocampal CA1 area. *European Journal of Pharmacology*, 422(1–3), pp.69–76.
- Joshi, S.R., Ghattamaneni, R.B. and Scovell, W.M., 2011. Expanding the paradigm for estrogen receptor binding and transcriptional activation. *Molecular Endocrinology*, 25(6), pp.980–994.
- Kaleyias, J., Tzoufi, M., Kotsalis, C., Papavasiliou, A. and Diamantopoulos, N., 2005. Knowledge and attitude of the Greek educational community toward epilepsy and the epileptic student. *Epilepsy and Behavior*, 6(2), pp.179–186.
- Kalilani, L., Sun, X., Pelgrims, B., Noack-Rink, M. and Villanueva, V., 2018. The epidemiology of drug-resistant epilepsy: A systematic review and meta-analysis. *Epilepsia*, 59(12), pp.2179–2193.
- Kamaşak, T., Dilber, B., Yaman, S.O., Durgut, B.D., Kurt, T., Coban, E., *et al.*, 2020. HMGB-1, TLR4, IL-1R1, TNF- α , and IL-1 β : novel epilepsy markers? *Epileptic Disorders*, 22(2), pp.183–193.
- Kan, M., Song, L., Zhang, X., Zhang, J. and Fang, P., 2019. Circulating high mobility group box-1 and toll-like receptor 4 expressions increase the risk and severity of epilepsy. *Brazilian Journal of Medical and Biological Research*, 52(7), pp.1–7.
- Kannan, V., Pareek, A. V., Das, A.R., Gay, C.T. and Riviello, J.J., 2023. “Fifth-day fits” revisited: A literature review of benign idiopathic neonatal seizures and comparison with KCNQ2- and KCNQ3-associated benign familial epilepsy syndromes. *Annals of the Child Neurology Society*, 1(3), pp.202–208.
- Kobylarek, D., Iwanowski, P., Lewandowska, Z., Limphaibool, N., Szafranek, S., Labrzycka, A., *et al.*, 2019. Advances in the potential biomarkers of epilepsy. *Frontiers in Neurology*, 10(JUL).
- Kossoff, E.H., 2011. Intractable Childhood Epilepsy: Choosing Between the Treatments. *Seminars in Pediatric Neurology*, 18(3), pp.145–149. Terdapat di: <http://dx.doi.org/10.1016/j.spn.2011.06.001>.
- Kwan, P., Arzimanoglou, A., Berg, A.T., Brodie, M.J., Hauser, W.A., Mathern, G., *et al.*, 2010. Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. *Epilepsia*, 51(6), pp.1069–1077.
- Lee, Y.J., Hwang, S.K. and Kwon, S., 2017. The Clinical Spectrum of Benign

- Epilepsy with Centro-Temporal Spikes: a Challenge in Categorization and Predictability. *Journal of Epilepsy Research*, 7(1), pp.1–6.
- Leitner, G.R., Wenzel, T.J., Marshall, N., Gates, E.J. and Klegeris, A., 2019. Targeting toll-like receptor 4 to modulate neuroinflammation in central nervous system disorders. *Expert Opinion on Therapeutic Targets*, 23(10), pp.865–882. Terdapat di: <https://doi.org/10.1080/14728222.2019.1676416>.
- Leow-Dyke, S., Allen, C., Denes, A., Nilsson, O., Maysami, S., Bowie, A.G., *et al.*, 2012. Neuronal toll-like receptor 4 signaling induces brain endothelial activation and neutrophil transmigration in vitro. *Journal of Neuroinflammation*, 9, pp.1–11.
- Li, B., Peng, X., Li, H., Chen, F., Chen, Y., Zhang, Y., *et al.*, 2021. The performance of the alarmin HMGB1 in pediatric diseases: From lab to clinic. *Immunity, Inflammation and Disease*, 9(1), pp.8–30.
- Li, G., Wu, X., Yang, L., He, Y., Liu, Y., Jin, X., *et al.*, 2016. TLR4-mediated NF- κ B signaling pathway mediates HMGB1-induced pancreatic injury in mice with severe acute pancreatitis. *International Journal of Molecular Medicine*, 37(1), pp.99–107.
- Li, T., Gao, Q. and Luan, G., 2016. HMGB1-TLR Signaling in Rasmussens Encephalitis. *Journal of Neuroinfectious Diseases*, 7(3).
- Lillywhite, L.M., Saling, M.M., Simon Harvey, A., Abbott, D.F., Archer, J.S., Vears, D.F., *et al.*, 2009. Neuropsychological and functional MRI studies provide converging evidence of anterior language dysfunction in BECTS. *Epilepsia*, 50(10), pp.2276–2284.
- Liu, K., Mori, S., Takahashi, H.K., Tomono, Y., Wake, H., Kanke, T., *et al.*, 2007. Anti-high mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats. *The FASEB Journal*, 21(14), pp.3904–3916.
- Löscher, W., Potschka, H., Sisodiya, S.M. and Vezzani, A., 2020. Drug resistance in epilepsy: Clinical impact, potential mechanisms, and new innovative treatment options. *Pharmacological Reviews*, 72(3), pp.606–638.
- Luo, L., Jin, Y., Kim, I.D. and Lee, J.K., 2014. Glycyrrhizin Suppresses HMGB1 Inductions in the Hippocampus and Subsequent Accumulation in Serum of a Kainic Acid-Induced Seizure Mouse Model. *Cellular and Molecular Neurobiology*, 34(7), pp.987–997.
- Magna, M. and Pisetsky, D.S., 2014. The role of HMGB1 in the pathogenesis of inflammatory and autoimmune diseases. *Molecular Medicine*, 20(1), pp.138–146.
- Mangunatmadja, I., Indra, R.M., Widodo, D.P. and Rafli, A., 2021. Risk Factors for Drug Resistance in Epileptic Children with Age of Onset above Five Years: A Case-Control Study. *Behavioural Neurology*, 2021.
- Maroso, M., Balosso, S., Ravizza, T., Liu, J., Aronica, E., Iyer, A.M., *et al.*, 2010. Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. *Nature Medicine*, 16(4), pp.413–419. Terdapat di: <http://dx.doi.org/10.1038/nm.2127>.

- Matoth, I., Pinto, F., Sicsic, C. and Brenner, T., 2000. Inhibitory effect of carbamazepine on inflammatory mediators produced by stimulated glial cells. *Neuroscience Research*, 38(2), pp.209–212.
- Mazarati, A., Maroso, M., Iori, V., Vezzani, A. and Carli, M., 2011. High-mobility group box-1 impairs memory in mice through both toll-like receptor 4 and Receptor for Advanced Glycation End Products. *Experimental Neurology*, 232(2), pp.143–148.
- Mazarati, A., Maroso, M., Iori, V., Vezzani, A. and Carli, M., 2011. High-mobility group box-1 impairs memory in mice through both toll-like receptor 4 and Receptor for Advanced Glycation End Products. *Experimental Neurology*, 232(2), pp.143–148. Terdapat di:
<http://dx.doi.org/10.1016/j.expneurol.2011.08.012>.
- Medzhitov, R., Preston-hurlburt, P. and Jr, C.A.J., 2012. Widow of Nepali shot by PC seeks compensation. *South China Morning Post*, 388(July), pp.6–9. Terdapat di:
<http://www.scmp.com/article/995826/widow-nepali-shot-pc-seeks-compensation>.
- Meng, Q., Bi, Y., Feng, H., Ding, X., Zhang, S., Chen, Q., *et al.*, 2023. Activation of estrogen receptor α inhibits TLR4 signaling in macrophages and alleviates the instability of atherosclerotic plaques in the postmenopausal stage. *International Immunopharmacology*, 116(February), pp.1–15.
- Molteni, M., Gemma, S. and Rossetti, C., 2016. The Role of Toll-Like Receptor 4 in Infectious and Noninfectious Inflammation. *Mediators of Inflammation*, 2016.
- Morichi, S., Yamanaka, G., Watanabe, Y., Takamatsu, T., Kasuga, A., Takeshita, M., *et al.*, 2021. High mobility group box 1 and angiogenetic growth factor levels in children with central nerve system infections. *Journal of Infection and Chemotherapy*, 27(6), pp.840–844. Terdapat di:
<https://doi.org/10.1016/j.jiac.2021.01.019>.
- Mukai, T., Kinboshi, M., Nagao, Y., Shimizu, S., Ono, A., Sakagami, Y., *et al.*, 2018. Antiepileptic drugs elevate astrocytic Kir4.1 expression in the rat limbic region. *Frontiers in Pharmacology*, 9(8), pp.1–9.
- Musumeci, D., Roviello, G.N. and Montesarchio, D., 2014. An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies. *Pharmacology and Therapeutics*, 141(3), pp.347–357. Terdapat di:
<http://dx.doi.org/10.1016/j.pharmthera.2013.11.001>.
- Nguyen, Y.T.M., Vu, B.Q., Nguyen, D.K., Quach, N.V., Bui, L.T., Hong, J., *et al.*, 2024. Genotype-driven therapeutics in DEE and metabolic epilepsy: navigating treatment efficacy and drug resistance. *Scientific Reports*, 14(1), pp.1–13.
- Ouyang, M., Dubois, J., Yu, Q., Mukherjee, P. and Huang, H., 2019. Delineation of early brain development from fetuses to infants with diffusion MRI and beyond. *NeuroImage*, 185(April 2018), pp.836–850. Terdapat di:
<https://doi.org/10.1016/j.neuroimage.2018.04.017>.
- Paudel, Y.N., Angelopoulou, E., Akyuz, E., Piperi, C., Othman, I. and Shaikh, M.F., 2020. Role of Innate Immune Receptor TLR4 and its endogenous ligands in

- epileptogenesis. *Pharmacological Research*, 160(August), p.105172. Terdapat di: <https://doi.org/10.1016/j.phrs.2020.105172>.
- Paudel, Y.N., Semple, B.D., Jones, N.C., Othman, I. and Shaikh, M.F., 2019. High mobility group box 1 (HMGB1) as a novel frontier in epileptogenesis: from pathogenesis to therapeutic approaches. *Journal of Neurochemistry*, 151(5), pp.542–557.
- Paudel, Y.N., Shaikh, M.F., Chakraborti, A., Kumari, Y., Aledo-Serrano, Á., Aleksovska, K., *et al.*, 2018. HMGB1: A common biomarker and potential target for TBI, neuroinflammation, epilepsy, and cognitive dysfunction. *Frontiers in Neuroscience*, 12(SEP), pp.1–19.
- Qin, Y.-H., Dai, S.-M., Tang, G.-S., Zhang, J., Ren, D., Wang, Z.-W., *et al.*, 2009. HMGB1 Enhances the Proinflammatory Activity of Lipopolysaccharide by Promoting the Phosphorylation of MAPK p38 through Receptor for Advanced Glycation End Products. *The Journal of Immunology*, 183(10), pp.6244–6250.
- Raga, S., Specchio, N., Rheims, S. and Wilmschurst, J.M., 2021. Developmental and epileptic encephalopathies: recognition and approaches to care. *Epileptic Disorders*, 23(1), pp.40–52.
- Ravizza, T., Terrone, G., Salamone, A., Frigerio, F., Balosso, S., Antoine, D.J., *et al.*, 2018. High Mobility Group Box 1 is a novel pathogenic factor and a mechanistic biomarker for epilepsy. *Brain, Behavior, and Immunity*, 72, pp.14–21. Terdapat di: <http://dx.doi.org/10.1016/j.bbi.2017.10.008>.
- Reid, A.Y., Riazi, K., Campbell Teskey, G. and Pittman, Q.J., 2013. Increased excitability and molecular changes in adult rats after a febrile seizure. *Epilepsia*, 54(4), pp.1–4.
- Rodgers, K.M., Hutchinson, M.R., Northcutt, A., Maier, S.F., Watkins, L.R. and Barth, D.S., 2009. The cortical innate immune response increases local neuronal excitability leading to seizures. *Brain*, 132(9), pp.2478–2486.
- Salih, K.S., Hamdan, F.B. and Al-Mayah, Q.S., 2020. Diagnostic value of matrix metalloproteinase-2 and high mobility group box 1 in patients with refractory epilepsy. *Egyptian Journal of Neurology, Psychiatry and Neurosurgery*, 56(1).
- Santana-Gomez, C.E., Engel, J. and Staba, R., 2022. Drug-resistant epilepsy and the hypothesis of intrinsic severity: What about the high-frequency oscillations? *Epilepsia Open*, 7(S1), pp.S59–S67.
- Sarkis, R.A., Goksen, Y., Mu, Y., Rosner, B. and Lee, J.W., 2018. Cognitive and fatigue side effects of anti-epileptic drugs: an analysis of phase III add-on trials. *Journal of Neurology*, 265(9), pp.2137–2142. Terdapat di: <http://dx.doi.org/10.1007/s00415-018-8971-z>.
- Scaffidi, P., Misteli, T. and Bianchi, M.E., 2002. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. *Nature*, 418(6894), pp.191–195.
- Scheffer, I.E., Berkovic, S., Capovilla, G., Connolly, M.B., French, J., Guilhoto, L., *et al.*, 2017. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. *Epilepsia*, 58(4), pp.512–521.

- Scher, M.S., 2017. *Pediatric Neurophysiologic Evaluation* Sixth Edit., Elsevier Inc. Terdapat di: <http://dx.doi.org/10.1016/B978-0-323-37101-8.00013-8>.
- Scovell, W.M., 2016. High mobility group protein 1: A collaborator in nucleosome dynamics and estrogen-responsive gene expression. *World Journal of Biological Chemistry*, 7(2), p.206.
- Shi, Y., Zhang, L., Teng, J. and Miao, W., 2018. HMGB1 mediates microglia activation via the TLR4/NF- κ B pathway in coriaria lactone induced epilepsy. *Molecular Medicine Reports*, 17(4), pp.5125–5131.
- Spencer, S.J., Martin, S., Mouihate, A. and Pittman, Q.J., 2006. Early-life immune challenge: Defining a critical window for effects on adult responses to immune challenge. *Neuropsychopharmacology*, 31(9), pp.1910–1918.
- Steinlein, O.K., 2014. *Mechanisms underlying epilepsies associated with sodium channel mutations* 1st ed., Elsevier B.V. Terdapat di: <http://dx.doi.org/10.1016/B978-0-444-63326-2.00005-3>.
- Swanson, L.C. and Ahmed, R., 2022. Epilepsy Syndromes: Current Classifications and Future Directions. *Neurosurgery Clinics of North America*, 33(1), pp.113–134. Terdapat di: <https://doi.org/10.1016/j.nec.2021.09.009>.
- Toga, A.W., Thompson, P.M. and Sowell, E.R., 2006. Mapping brain maturation. *Trends in Neurosciences*, 29(3), pp.148–159.
- Tripathi, A., Shrinet, K. and Kumar, A., 2019. HMGB1 protein as a novel target for cancer. *Toxicology Reports*, 6(February), pp.253–261. Terdapat di: <https://doi.org/10.1016/j.toxrep.2019.03.002>.
- Ulloa, L. and Messmer, D., 2006. High-mobility group box 1 (HMGB1) protein: Friend and foe. *Cytokine and Growth Factor Reviews*, 17(3), pp.189–201.
- Ümit Sayin, H., 2017. A bio-electrical tornado in the hippocampus: Mechanisms of temporal lobe epilepsy. *NeuroQuantology*, 15(1), pp.92–103.
- Urio, O.H., Kija, E., Weckhuysen, S., Makungu, H. and Naburi, H., 2024. Drug resistant epilepsy and associated factors among children with epilepsies in tanzania: a cross-sectional study. *BMC Neurology*, 24(1), pp.4–10.
- Van Vliet, E.A., Aronica, E. and Gorter, J.A., 2015. Blood-brain barrier dysfunction, seizures and epilepsy. *Seminars in Cell and Developmental Biology*, 38, pp.26–34. Terdapat di: <http://dx.doi.org/10.1016/j.semcdb.2014.10.003>.
- Velísková, J. and DeSantis, K.A., 2013. Sex and hormonal influences on seizures and epilepsy. *Hormones and Behavior*, 63(2), pp.267–277.
- Vezzani, A. and Viviani, B., 2015. Neuromodulatory properties of inflammatory cytokines and their impact on neuronal excitability. *Neuropharmacology*, 96(PA), pp.70–82. Terdapat di: <http://dx.doi.org/10.1016/j.neuropharm.2014.10.027>.
- Von Rüden, E.L., Gualtieri, F., Schönhoff, K., Reiber, M., Wolf, F., Baumgärtner, W., et al., 2020. Molecular alterations of the TLR4-signaling cascade in canine epilepsy. *BMC Veterinary Research*, 16(1), pp.1–14.
- Walker, L. and Sills, G.J., 2012. Inflammation and epilepsy: The foundations for a new therapeutic approach in epilepsy? *Epilepsy Currents*, 12(1), pp.8–12.

- Walker, L., Tse, K., Ricci, E., Thippeswamy, T., Sills, G.J., White, S.H., *et al.*, 2014. High mobility group box 1 in the inflammatory pathogenesis of epilepsy: profiling circulating levels after experimental and clinical seizures. *The Lancet*, 383, p.S105. Terdapat di: [http://dx.doi.org/10.1016/S0140-6736\(14\)60368-8](http://dx.doi.org/10.1016/S0140-6736(14)60368-8).
- Walker, L.E., Sills, G.J., Jorgensen, A., Alapirtti, T., Peltola, J., Brodie, M.J., *et al.*, 2022. High-mobility group box 1 as a predictive biomarker for drug-resistant epilepsy: A proof-of-concept study. *Epilepsia*, 63(1), pp.e1–e6.
- Wang, G., Wu, W., Xu, Y., Yang, Z., Xiao, B. and Long, L., 2022. Imaging Genetics in Epilepsy: Current Knowledge and New Perspectives. *Frontiers in Molecular Neuroscience*, 15(May), pp.1–14.
- Wang, N., Liu, H., Ma, B., Zhao, T., Chen, Y., Yang, Y., *et al.*, 2021. CSF high-mobility group box 1 is associated with drug-resistance and symptomatic etiology in adult patients with epilepsy. *Epilepsy Research*, 177(September), p.106767. Terdapat di: <https://doi.org/10.1016/j.eplepsyres.2021.106767>.
- Wheless, J.W., 2012. Therapeutic Efficacy of Antiepileptic Drugs. *Epilepsy in Children and Adolescents*, pp.159–174.
- Wirrell, E.C., Grossardt, B.R., Wong-Kisiel, L.C.L. and Nickels, K.C., 2011. Incidence and classification of new-onset epilepsy and epilepsy syndromes in children in Olmsted County, Minnesota from 1980 to 2004: A population-based study. *Epilepsy Research*, 95(1–2), pp.110–118. Terdapat di: <http://dx.doi.org/10.1016/j.eplepsyres.2011.03.009>.
- Wolf, S.M. and McGoldrick, P.E., 2006. Recognition and management of pediatric seizures. *Pediatric Annals*, 35(5), pp.332–344.
- Xie, J., Méndez, J.D., Méndez-Valenzuela, V. and Aguilar-Hernández, M.M., 2013. Cellular signalling of the receptor for advanced glycation end products (RAGE). *Cellular Signalling*, 25(11), pp.2185–2197. Terdapat di: <http://dx.doi.org/10.1016/j.cellsig.2013.06.013>.
- Xu, T., Jiang, L. and Wang, Z., 2019. The progression of hmgb1-induced autophagy in cancer biology. *Oncotargets and Therapy*, 12, pp.365–377.
- Yang, H., Lundback, P., Ottoson, L., Erlandsson-Harris, H., Venereau, E., Bianchi, M.E, *et al.*, 2012. Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). *Molecular Medicine*, 18(2), pp.250–259.
- Yang, H., Wang, H. and Andersson, U., 2020. Targeting Inflammation Driven by HMGB1. *Frontiers in Immunology*, 11(March), pp.1–9.
- Yang, Lijun, Wang, F., Yang, Liang, Yuan, Y., Chen, Y., Zhang, G., *et al.*, 2018. HMGB1 a-Box Reverses Brain Edema and Deterioration of Neurological Function in a Traumatic Brain Injury Mouse Model. *Cellular Physiology and Biochemistry*, 46(6), pp.2532–2542.
- Yang, W., Li, J., Shang, Y., Zhao, L., Wang, M., Shi, J., *et al.*, 2017. HMGB1-TLR4 Axis Plays a Regulatory Role in the Pathogenesis of Mesial Temporal Lobe Epilepsy in Immature Rat Model and Children via the p38MAPK Signaling Pathway. *Neurochemical Research*, 42(4), pp.1179–1190.

- Ye, Y., Zeng, Z., Jin, T., Zhang, H., Xiong, X. and Gu, L., 2019. The role of high mobility group box 1 in ischemic stroke. *Frontiers in Cellular Neuroscience*, 13(April), pp.1–12.
- Yue, Z., Tang, J., Peng, S., Cai, X., Rong, X. and Yang, L., 2023. Serum concentration of high-mobility group box 1, Toll-like receptor 4 as biomarker in epileptic patients. *Epilepsy Research*, 192(January), p.107138. Terdapat di: <https://doi.org/10.1016/j.eplepsyres.2023.107138>.
- Zhao, J., Wang, Y., Xu, C., Liu, K., Wang, Y., Chen, L., *et al.*, 2017. Therapeutic potential of an anti-high mobility group box-1 monoclonal antibody in epilepsy. *Brain, Behavior, and Immunity*, 64, pp.308–319. Terdapat di: <http://dx.doi.org/10.1016/j.bbi.2017.02.002>.
- Zhu, M., Chen, J., Guo, H., Ding, L., Zhang, Y. and Xu, Y., 2018. High Mobility Group Protein B1 (HMGB1) and Interleukin-1 β as Prognostic Biomarkers of Epilepsy in Children. *Journal of Child Neurology*, 33(14), pp.909–917.
- Zurolo, E., Iyer, A., Maroso, M., Carbonell, C., Anink, J.J., Ravizza, T., *et al.*, 2011. Activation of toll-like receptor, RAGE and HMGB1 signalling in malformations of cortical development. *Brain*, 134(4), pp.1015–1032.